Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
株式のランク #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
株価
$0.11725176
最終同期: 2025-07-14
時価総額
$481.50K
変化(1日)
-0.20%
変化(1年)
0.00%
FR
取引 PHAXIAM Therapeutics S.A. (PHXM)

カテゴリー

PHAXIAM Therapeutics S.A.(PHXM)の発行済株式数
June 2024 時点の発行済株式数 6.07M
PHAXIAM Therapeutics S.A. の最新の財務報告および株価によると、現在の発行済株式数は 6.07M です。December 2022 の終わりには、同社は 3.36M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
PHAXIAM Therapeutics S.A.(PHXM)の発行済株式数の履歴(2016 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 6.07M 29.39%
2023 4.70M 39.91%
2022 3.36M 30.91%
2021 2.56M 28.86%
2020 1.99M 2.50%
2019 1.94M 0.00%
2018 1.94M 57.75%
2017 1.23M 42.42%
2016 863.80K 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M 4,079.52%
US
62.19M 923.65%
NL
- -
CH
- -
KR
0.00 -100.00%
BE